What is Allos?
Allos operates at the intersection of quantum physics, applied artificial intelligence, and pharmaceutical science. The company specializes in the reformulation of small-molecule drugs, utilizing its unique Causal AI engine to enhance drug safety and bioavailability. By integrating real-world evidence derived from extensive health records, Allos provides a robust framework for designing clinical studies that are both faster and more reliable than traditional methodologies.
The company's market position is defined by its ability to unlock stalled pharmaceutical programs and modernize legacy assets, offering a high-value proposition to established industry players. By combining deep scientific expertise with a data-native approach, Allos is effectively transforming the drug development lifecycle, reducing the inherent risks associated with bringing complex medicines to market.
How much funding has Allos raised?
Allos has raised a total of $5M across 1 funding round:
Seed
$5M
Seed (2026): $5M with participation from Oxford Sciences Enterprises, Berkeley SkyDeck Fund, and Habico Invest
Key Investors in Allos
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent, billion-pound investment company created in 2015 to found, fund and build transformational businesses via the company's unique partnership with the University of Oxford, the worlds #1 research university.
Berkeley SkyDeck Fund
Berkeley SkyDeck is a premier startup accelerator program affiliated with the University of California, Berkeley, designed to support early-stage startups through investment, mentorship, and access to a vast network of advisors and industry partners.
Habico Invest
Habico Invest A/S is a Danish family office founded by Birgitte and Hans Bøgh-Sørensen that specializes in investments across a wide range of asset classes to provide strategic financial growth.
What's next for Allos?
Looking ahead, the strategic deployment of this capital will focus on scaling the company's clinical trial design capabilities and deepening its collaborative efforts with major pharmaceutical partners. As Allos continues to refine its Causal AI models, the focus will shift toward expanding its portfolio of reformulated medicines and establishing a new standard for evidence-based drug development.
The company is expected to leverage its recent funding to bolster its research team and enhance its data infrastructure, ensuring that it remains at the forefront of the AI-driven biotech revolution. By maintaining a rigorous focus on clinical efficacy and regulatory compliance, Allos is poised to capture significant market share, ultimately improving patient access to high-quality, modernized therapeutic solutions.
